•IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile

（Horton, H. M., Dorigo, O., Hernandez, P., Anderson, D., Berek, J. S., & Parker, S. E. (1999). IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. JOURNAL OF IMMUNOLOGY, 163(12), 6378–6385.）

•A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature
（Ghosh, K., Dorigo, O., Bristow, R., & Berek, J. (2000). A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 191(2), 212–215.）

•Specific keynote: Immunological therapy for ovarian cancer
（Berek, J. S., Dorigo, O., Schultes, B., & Nicodemus, C. (2003). Specific keynote: Immunological therapy for ovarian cancer. GYNECOLOGIC ONCOLOGY, 88(1), S105–S109.)